BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 21075543)

  • 1. Possible roles of B lymphocyte activating factor of the tumour necrosis factor family in vitiligo autoimmunity.
    Lin X; Tian H; Xianmin M
    Med Hypotheses; 2011 Mar; 76(3):339-42. PubMed ID: 21075543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions.
    Lambe T; Leung JC; Bouriez-Jones T; Silver K; Makinen K; Crockford TL; Ferry H; Forrester JV; Cornall RJ
    J Immunol; 2006 Sep; 177(5):3055-62. PubMed ID: 16920942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of mouse T lymphocyte-induced suppression of the IgG2ab allotype and T lymphocyte tolerance to IgG2ab.
    Majlessi L; Bordenave G
    Arch Immunol Ther Exp (Warsz); 2001; 49(6):407-15. PubMed ID: 11814234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of immune hyporesponsiveness to melanosomal proteins by DHICA-mediated antioxidation: Possible implications for autoimmune vitiligo.
    Liu XM; Zhou Q; Xu SZ; Wakamatsu K; Lei TC
    Free Radic Biol Med; 2011 May; 50(9):1177-85. PubMed ID: 21256957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopathogenesis of vitiligo.
    Sandoval-Cruz M; García-Carrasco M; Sánchez-Porras R; Mendoza-Pinto C; Jiménez-Hernández M; Munguía-Realpozo P; Ruiz-Argüelles A
    Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.
    Kemp EH; Gavalas NG; Gawkrodger DJ; Weetman AP
    Autoimmun Rev; 2007 Jan; 6(3):138-42. PubMed ID: 17289548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo.
    Steitz J; Wenzel J; Gaffal E; Tüting T
    Eur J Cell Biol; 2004 Dec; 83(11-12):797-803. PubMed ID: 15679123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N; Gavalas NG; Weetman AP; Kemp EH
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinations of B cell fate in immunity and autoimmunity.
    Noelle RJ; Erickson LD
    Curr Dir Autoimmun; 2005; 8():1-24. PubMed ID: 15564715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of B cell self-tolerance by BAFF.
    Brink R
    Semin Immunol; 2006 Oct; 18(5):276-83. PubMed ID: 16916609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immunohistological study of cutaneous lymphocytes in vitiligo.
    Badri AM; Todd PM; Garioch JJ; Gudgeon JE; Stewart DG; Goudie RB
    J Pathol; 1993 Jun; 170(2):149-55. PubMed ID: 8345407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of BAFF in immune function and implications for autoimmunity.
    Kalled SL
    Immunol Rev; 2005 Apr; 204():43-54. PubMed ID: 15790349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo.
    Ben Ahmed M; Zaraa I; Rekik R; Elbeldi-Ferchiou A; Kourda N; Belhadj Hmida N; Abdeladhim M; Karoui O; Ben Osman A; Mokni M; Louzir H
    Pigment Cell Melanoma Res; 2012 Jan; 25(1):99-109. PubMed ID: 21985183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sites and stages of autoreactive B cell activation and regulation.
    Shlomchik MJ
    Immunity; 2008 Jan; 28(1):18-28. PubMed ID: 18199415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunological basis of B-cell therapy in systemic lupus erythematosus.
    Mok MY
    Int J Rheum Dis; 2010 Feb; 13(1):3-11. PubMed ID: 20374380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitiligo, reactive oxygen species and T-cells.
    Glassman SJ
    Clin Sci (Lond); 2011 Feb; 120(3):99-120. PubMed ID: 20958268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c.
    Mamula MJ; Lin RH; Janeway CA; Hardin JA
    J Immunol; 1992 Aug; 149(3):789-95. PubMed ID: 1321851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakdown of self-tolerance and the pathogenesis of autoimmunity.
    Ring GH; Lakkis FG
    Semin Nephrol; 1999 Jan; 19(1):25-33. PubMed ID: 9952278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-reactive anti-class II T helper type 2 cell lines derived from gold salt-injected rats trigger B cell polycolonal activation and transfer autoimmunity in CD8-depleted normal syngeneic recipients.
    Saoudi A; Castedo M; Nochy D; Mandet C; Pasquier R; Druet P; Pelletier L
    Eur J Immunol; 1995 Jul; 25(7):1972-9. PubMed ID: 7621873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.